Gene Solutions at ESMO TAT Asia 2025

Innovation and collaboration defined ESMO TAT Asia 2025. ESMO TAT’s first event in Asia attracted over 600 oncologists and healthcare professionals from 16 countries and territories.

🔬 Gene Solutions, in collaboration with the Medical Genetics Institute Vietnam, was proud to promote 11 innovative and promising studies at ESMO TAT Asia 2025 – selected from among 66 posters and 13 ePosters. Highlights of our research include:
❇️ AI-powered neoantigen & TCR selection for personalized cancer vaccines and TCR-T therapy;
❇️ ctDNA assays & multi-omics profiling for real-time monitoring and tailored treatment;
❇️ Novel immunotherapy targets – from KRASG12V bispecific engagers to NK ligand signatures;
❇️ Patient-derived organoid biobank for precision drug screening.

In addition, during the event, we had the opportunity to introduce two key innovations that are pushing the boundaries of precision oncology:
⭐ K-4CARE™ MAX: A comprehensive genomic and transcriptomic profiling solution for clinical research use only, featuring whole exome sequencing (DNA), 19,435 genes (RNA), and an ultra-sensitive ctDNA-MRD assay. It also includes exploratory biomarkers such as Tumor Neoantigen Burden and Tumor Microenvironment to support clinical trials in precision oncology.
⭐ DNASphere.AI Platform: A Unified AI Platform to improve Genetic Testing and Unlock Insights for the Rapid Identification and Validation of Novel Therapeutic Targets.

These efforts reflect our mission to transform cutting-edge science into accessible, region-specific cancer care—globally.

Thank you #ESMOTAT #ESMOTATAsia2025